Management of Angiotensin Receptor Blockers in Acute Kidney Injury

Introduction to ARB Risks

The American College of Cardiology and other guideline societies recommend avoiding ARBs in patients with acute kidney injury (AKI) as they can exacerbate kidney dysfunction and increase the risk of acute kidney disease (AKD) 1, 2
ARBs directly affect renal hemodynamics by blocking angiotensin II receptors, which can decrease glomerular filtration pressure and further compromise already impaired kidney function in AKI patients 1
ARBs are recognized as potential nephrotoxins that should be avoided when a patient has AKI, especially when alternative antihypertensive medications with less nephrotoxic potential are available 2, 3

Patient Selection for ARB Avoidance

Patients with known risk factors for kidney injury (advanced age, previous AKI episodes, chronic kidney disease, diabetes, proteinuria, hypertension) should avoid ARBs 2
ARBs should be avoided when a suitable and less nephrotoxic alternative is available 2
The use of ARBs is considered non-essential for the patient's condition and should be avoided 2
Patients already receiving another nephrotoxic drug should avoid ARBs 2
There is concern about lack of appropriate follow-up of serum creatinine and/or drug concentration monitoring, and ARBs should be avoided 2

Alternative Antihypertensive Options

Calcium channel blockers (CCBs), particularly dihydropyridines like amlodipine, have minimal effects on renal hemodynamics and can be used as alternatives 4, 5
Thiazide-like diuretics (e.g., chlorthalidone) can be used in mild-moderate AKI, though they should be used with caution 5
Loop diuretics (e.g., furosemide) are preferred in patients with volume overload and moderate-to-severe kidney dysfunction 6
Beta-blockers can be used if the patient has concomitant ischemic heart disease or heart failure 6

Special Considerations for ARB Use

If the patient was previously on an ARB, it should be discontinued during the AKI episode and potentially reintroduced only after GFR has stabilized and volume status is optimized 1, 2
Consider reintroducing ARBs only after GFR has stabilized and volume status is optimized 1
Start with lower doses and titrate slowly while monitoring renal function and potassium levels 5
The risk-benefit ratio must be carefully considered and therapy personalized according to individual patient risks 1

Discontinuation of Losartan in Acute Kidney Injury

Evidence and Recommendations

The Kidney Disease: Improving Global Outcomes (KDIGO) conference identified the need for research on the timing of ACE-I/ARBs discontinuation and re-initiation in AKI/AKD in different clinical contexts 7
The Acute Disease Quality Initiative (ADQI) workgroup recommends that drug selection in AKI should be guided by the functional phase, trajectory, and stage of kidney injury 8, 9
The decision to reintroduce ARBs after AKI resolution should be individualized based on the patient's underlying conditions, with careful monitoring of kidney function 8, 10

Management of Irbesartan in Acute Kidney Injury

Temporary Suspension and Reintroduction

The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend temporarily suspending RAAS antagonists, including ARBs like irbesartan, during high-risk periods such as intercurrent illness, planned IV radiocontrast administration, bowel preparation prior to colonoscopy, and major surgery, in patients with acute kidney injury (AKI) 11
The KDOQI guidelines explicitly state that RAAS antagonists should not be routinely discontinued in people with GFR < 30 ml/min/1.73 m² as they remain nephroprotective 11
When reintroducing irbesartan after AKI, it is recommended to wait for stabilization of GFR, optimization of volume status, and resolution of acute illness, and then assess renal function and serum potassium within 1 week of restarting 11

Monitoring and Dose Adjustment

The KDOQI guidelines recommend monitoring GFR and serum potassium within 1 week of restarting irbesartan after AKI, and adjusting the dose as needed 11

Restarting Losartan After Acute Hemodynamic Renal Failure

Introduction to Restarting Losartan

The American College of Cardiology recommends that losartan can be safely restarted after an episode of acute renal failure, particularly if the underlying condition is managed, with a similar principle applying to ACE inhibitors 12

Protocol for Restarting Losartan

The American Heart Association suggests that the mean arterial pressure should be >65 mm Hg to avoid symptomatic hypotension when restarting losartan 12
An increase in serum creatinine of 10-20% is considered acceptable and does not require suspension of losartan 13

Contraindications for Restarting Losartan

The American College of Cardiology states that losartan should not be restarted if the patient has a serum potassium level >5.5 mEq/L 14

Alternative Antihypertensive Therapies

The American College of Cardiology recommends using dihydropyridine calcium channel blockers (such as amlodipine 2.5-10 mg daily) as an alternative to losartan during the acute phase, as they have minimal effects on renal hemodynamics 14, 13
The American Heart Association suggests using loop diuretics (such as furosemide) in patients with volume overload and moderate to severe renal dysfunction 14, 13
Beta blockers can be used if there is concomitant ischemic heart disease or heart failure 14, 13
Thiazide diuretics can be used only in mild to moderate acute renal failure (GFR >30 mL/min) 14, 13

Important Considerations for Restarting Losartan

The American College of Cardiology advises against combining losartan with ACE inhibitors or direct renin inhibitors due to the substantially increased risk of hyperkalemia and hypotension 14, 13
The American Heart Association recommends avoiding the use of potassium supplements or potassium-sparing diuretics concomitantly with losartan 14, 13

ACE/ARB Cessation and Reintroduction in Acute Kidney Injury

Introduction to ACE/ARB Management

The American College of Cardiology and other guideline societies recommend that ACE inhibitors and ARBs should be temporarily discontinued during acute kidney injury, as they can exacerbate kidney dysfunction through hemodynamic effects on glomerular filtration pressure 15

Reintroduction After AKI Resolution

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline society identified the need for more research on timing of ACE/ARB discontinuation and re-initiation, but the most recent and highest quality observational data consistently shows harm from permanent discontinuation after AKI recovery 16
ACE/ARBs should be reintroduced after GFR has stabilized and volume status is optimized, as continuing these medications after AKI recovery is associated with reduced mortality and cardiovascular events without increased recurrent AKI risk 15

Acute Kidney Injury Management with Losartan

Introduction to Losartan Contraindications

The American College of Cardiology and other guideline societies recommend avoiding losartan in patients with ongoing acute kidney injury, as it can worsen renal function by blocking angiotensin II receptors and decreasing glomerular filtration pressure 17

High-Risk Clinical Scenarios

The FDA and consensus guidelines identify specific situations where losartan poses particular danger during AKI, including volume depletion, bilateral renal artery stenosis, severe congestive heart failure, pre-existing chronic kidney disease, and advanced age 17

When to Consider Reintroducing Losartan After AKI Resolution

Losartan should only be reintroduced after the patient's GFR has stabilized, volume status is optimized, the acute illness has resolved, mean arterial pressure is greater than 65 mmHg, and serum potassium is less than 5.5 mEq/L, according to the Nature Reviews Nephrology 17

Critical Safety Monitoring

The FDA recommends monitoring serum creatinine, eGFR, and potassium within 1 week of restarting losartan after AKI recovery, and discontinuing immediately if creatinine rises more than 20% or potassium exceeds 5.5 mEq/L, as stated in the Nature Reviews Nephrology 17

Management of ACE‑Inhibitors and ARBs in Acute Kidney Injury

When to Suspend ACEI/ARB

Immediate suspension is required when acute kidney injury (AKI) occurs together with hemodynamic instability or extracellular‑fluid depletion, because blockade of angiotensin II reduces glomerular filtration pressure that is essential for perfusion of compromised kidneys. 18
Stop the drug during oliguria or anuria, as ACEI/ARB‑related AKI frequently presents with these findings and with hyperkalaemia. 18
Discontinue ACEI/ARB if serum creatinine rises ≥0.5 mg/dL (baseline ≤2.0 mg/dL) or ≥1.0 mg/dL (baseline > 2.0 mg/dL) after initiation, especially when the increase is progressive. 19
With concurrent diuretic use and extracellular‑fluid depletion, suspend ACEI/ARB and replace volume while stopping diuretics, the most effective strategy to resolve AKI. 18
Severe hypotension (mean arterial pressure < 65 mm Hg) mandates drug suspension, because renal filtration becomes highly dependent on angiotensin II under these conditions. 18
Bilateral renal‑artery stenosis or stenosis of a solitary kidney requires immediate discontinuation, as glomerular filtration is critically angiotensin‑II dependent. 18

Reversibility of ACEI/ARB‑Associated AKI

ACEI/ARB‑related AKI is almost always reversible, with renal function typically improving within 2–3 days after drug withdrawal when recognized before tubular injury develops. 18
The reversibility is explained by restoration of glomerular capillary pressure once endogenous angiotensin II production resumes after the blockade is lifted. 18
Do not replace a withdrawn ACEI with an ARB (or vice‑versa) during acute AKI, because both classes exert similar renal haemodynamic effects. 18

Criteria for Safe Re‑introduction

Renal function must be stable (estimated GFR not falling and no progressive creatinine rise) before restarting ACEI/ARB. 19
Volume status should be optimized, with resolution of any depletion or overload. 19
Serum potassium must be < 5.5 mEq/L, as hyperkalaemia is an absolute contraindication to re‑initiation. 20

Timing and Dosing of Re‑introduction

Restart the agent 2–3 days after normalization of renal function, reflecting the typical kinetic recovery of ACEI/ARB‑induced AKI. 18

Post‑re‑introduction Monitoring

Within the first week after restarting, assess serum creatinine, estimated GFR, and potassium to detect early deterioration. 20

Practical Considerations for High‑Risk Populations

Patients with prior myocardial infarction or heart‑failure should receive early re‑introduction, given the substantial mortality benefit of continued ACEI/ARB therapy. 18

Volume Management Prior to Re‑introduction

Correct extracellular‑fluid depletion and discontinue diuretics before re‑starting ACEI/ARB, as volume replacement is the most effective measure to resolve AKI. 18

Monitoring Protocol

Establish reliable baseline creatinine measurement and repeat it within one week of ACEI/ARB initiation, especially when oliguria or significant hypotension has occurred. 19